India accounts for about 20% of the worldwide provide of generic medicine and manufactures about 60,000 generic manufacturers, throughout 60 classes.
The plan comes towards the backdrop of the Centre’s transfer to bulk up its Manufacturing Linked incentive (PLI) scheme for generic medicine by together with extra molecules utilized in manufacturing key beginning supplies (KSMs), drug intermediates, and Lively Pharmaceutical Elements (APIs).
KSMs and intermediates are chemical compounds used to synthesize APIs, that are the primary parts of a drug.
“The federal government is engaged on a plan to impose a minimal import value on all PLI primarily based pharmaceutical merchandise. The plan is to guard the home trade in order that they can proceed to do the enterprise and to make India self-reliant,” stated one of many two folks talked about above.
The measure seeks to construct on India’s current success with home manufacturing of important antibiotics akin to Penicillin G. The API trade is an important phase of the pharmaceutical sector, accounting for about 35% of the market. Nevertheless, India depends on imports for 80% of its bulk drug requirement.
Bolstering self reliance
The transfer additionally goals to bolster India’s objective of self-reliance within the pharmaceutical sector. The heavy reliance on China, the world’s largest producer and exporter of APIs, creates important dangers for India’s drugs provide chain.
In 2021, the federal government launched the ₹15,000 crore PLI scheme for the prescription drugs sector. There are about 500 API producers in India, which account for about 8% of the worldwide API trade.
As well as, the manufacturing of APIs for important medicines can also be promoted via a devoted PLI scheme for bulk medicine, KSMs and APIs. The federal government is in search of new purposes because the earlier iteration of the PLI scheme failed to fulfill the expectations because of dumping of low cost commodities from China.
These schemes are aimed toward defending and inspiring home ingredient manufacturing which is seen as a important step in securing the long run development and stability of India’s pharma sector.
In response to the second individual, the plan is a direct response to appeals from the home API trade, which has struggled to compete with the low costs of Chinese language merchandise.
“Really, trade wants safety like some anti-dumping measures and MIP to make India self-reliant,” the second individual stated, referring to a apply the place a rustic ‘dumps’ its exports in different international locations at costs which are much less that what it prices to make these items.
Exports marginally larger
As per commerce ministry knowledge, India recorded a modest commerce surplus in bulk medicine and intermediates in FY25, with exports totalling $4.90 billion and imports at $4.64 billion. In FY24, exports stood at $4.79 billion, barely forward of imports value $4.56 billion, once more leading to a surplus. Equally, in FY23, exports had been $4.77 billion in comparison with imports of $4.51 billion, persevering with the development of a constructive commerce steadiness on this phase.
The Indian Medicine Producers’ Affiliation (IDMA) referred to as for a cautious and data-driven strategy to the proposal for imposing minimal import costs on choose APIs and KSMs. The trade physique has warned the federal government towards a blanket utility of the commerce measure.
“We consider {that a} data-backed, well-studied and balanced strategy must be thought-about,” stated Viranchi Shah, nationwide spokesperson for IDMA.
Whereas the transfer is meant to discourage low cost imports and assist the home pharma trade, Shah cautioned that India’s robust place in completed formulation exports should not be compromised.
“The minimal import value shouldn’t come as a blanket technique throughout the board, contemplating that India additionally has a really robust formulation trade,” he stated. “Our trade has to stay aggressive each domestically and globally.”
IDMA reiterated its assist to the federal government’s self-reliance push underneath the “Atma-Nirbhar Bharat” marketing campaign however urged coverage planners to make sure that commerce interventions like MIP don’t find yourself hampering Indian exports by making them extra expensive.
Queries despatched to the spokespersons of India’s commerce ministry, and division of prescription drugs on Friday and the Embassy of China in New Delhi on Saturday remained unanswered until the press time.
China dependent
Ajay Srivastava, co-founder of the World Commerce Analysis Initiative (GTRI), a coverage suppose tank, stated India’s chemical compounds and prescription drugs sector—which performs a vital function in healthcare, agriculture, and trade—is changing into closely depending on imports from China.
“This rising reliance not solely exposes India to provide chain vulnerabilities but additionally raises important strategic issues, particularly within the present international local weather the place geopolitical tensions and commerce disruptions are more and more frequent. Strengthening home manufacturing is thus not simply an financial precedence however a nationwide safety crucial,” he stated.
A GTRI report from April 2024 states that India’s imports of chemical compounds and prescription drugs reached $54.8 billion in FY2024. Between 2007 and 2022, China’s share in these imports rose sharply from 18% to 29%, with imports from China rising almost fourfold—from $4.4 billion to $17.4 billion.
Though imports from different international locations has additionally ballooned, the heavy dependence on China stays a significant strategic concern. In 2022, India’s chemical and pharmaceutical imports totaled $76.94 billion, with China accounting for 26.8%, adopted by Saudi Arabia, the US, Japan, and Russia.
There was a notable enhance in antibiotic imports from $551.2 million in 2007-10 to $1.27 billion in 2020-22, a rise of 130.7%. Right here too, China’s market share climbed to 81.7%, underscoring a excessive dependency on Chinese language pharmaceutical merchandise important for addressing widespread public well being wants in India, it stated.
Instrument of management
A minimal import value is an instrument utilized by international locations to manage surplus imports. As a working example, India has used MIPs to curb the import of metal and agricultural merchandise like onions and pulses.
By filtering out extraordinarily low-cost imports, MIP additionally helps preserve high quality requirements, guaranteeing that solely producers able to assembly cost-based compliance and high quality norms provide APIs to the Indian market.
“Whereas such a measure might result in a short-term enhance in enter prices for drug makers depending on Chinese language provides, it’s seen as a needed step for strengthening the home pharmaceutical ecosystem and lowering strategic vulnerabilities,” stated Abhash Kumar, a commerce economist and assistant professor of economics at Delhi College.
Additionally learn | India eyes Asean to spice up pharma exports
An MIP just isn’t outright banned underneath WTO guidelines, however it could possibly face challenges if used unfairly or for prolonged intervals. The WTO additionally permits rules-based devices like tariffs or anti-dumping duties backed by formal investigations.
India imposed an MIP on metal in 2016, however later changed it with WTO-compliant treatments like safeguard duties.
